PMV Pharmaceuticals Statistics
Total Valuation
PMVP has a market cap or net worth of $43.47 million. The enterprise value is -$119.73 million.
Important Dates
The last earnings date was Friday, May 9, 2025, before market open.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PMVP has 51.95 million shares outstanding. The number of shares has increased by 4.60% in one year.
| Current Share Class | 51.95M |
| Shares Outstanding | 51.95M |
| Shares Change (YoY) | +4.60% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 3.12% |
| Owned by Institutions (%) | 38.88% |
| Float | 33.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.28 |
| P/TBV Ratio | 0.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.75, with a Debt / Equity ratio of 0.01.
| Current Ratio | 16.75 |
| Quick Ratio | 16.43 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -32.66% and return on invested capital (ROIC) is -28.69%.
| Return on Equity (ROE) | -32.66% |
| Return on Assets (ROA) | -27.24% |
| Return on Invested Capital (ROIC) | -28.69% |
| Return on Capital Employed (ROCE) | -55.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.30M |
| Employee Count | 47 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -18.30M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.93% in the last 52 weeks. The beta is 1.49, so PMVP's price volatility has been higher than the market average.
| Beta (5Y) | 1.49 |
| 52-Week Price Change | -59.93% |
| 50-Day Moving Average | 1.05 |
| 200-Day Moving Average | 1.40 |
| Relative Strength Index (RSI) | 35.45 |
| Average Volume (20 Days) | 183,674 |
Short Selling Information
The latest short interest is 855,425, so 1.65% of the outstanding shares have been sold short.
| Short Interest | 855,425 |
| Short Previous Month | 838,637 |
| Short % of Shares Out | 1.65% |
| Short % of Float | 2.59% |
| Short Ratio (days to cover) | 6.40 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -88.79M |
| Pretax Income | -65.05M |
| Net Income | -60.88M |
| EBITDA | -87.98M |
| EBIT | -88.79M |
| Earnings Per Share (EPS) | -$1.18 |
Full Income StatementBalance Sheet
The company has $160.39 million in cash and $1.11 million in debt, giving a net cash position of $164.72 million or $3.17 per share.
| Cash & Cash Equivalents | 160.39M |
| Total Debt | 1.11M |
| Net Cash | 164.72M |
| Net Cash Per Share | $3.17 |
| Equity (Book Value) | 160.11M |
| Book Value Per Share | 3.08 |
| Working Capital | 153.74M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$53.36 million and capital expenditures -$65,000, giving a free cash flow of -$53.43 million.
| Operating Cash Flow | -53.36M |
| Capital Expenditures | -65,000 |
| Free Cash Flow | -53.43M |
| FCF Per Share | -$1.03 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |